Toward optimal use of corticosteroids in ulcerative colitis and Crohn's disease
Gastroenterologists have cause for pride in two classics of the medical literature. The collaborative trial of cortisone in ulcerative colitis was well timed, bold in concept and design, and a model of clarity. ' Over 20 years passed before a similar large scale trial was undertaken in active Crohn's disease but the result was the same: corticosteroid treatment was validated and its role was better defined. 2 The rationale of corticosteroid treatment in these two disorders remains unknown. In experimentally induced inflammation cor.ticosteroids decrease capillary permeability, reduce migration of macrophages and polymorphonuclear cells into the inflamed area, interfere with phagocytosis of antigens by macrophafes, stabilise lysosomal membranes, and inhibit cell-mediated immunity. Until we know the predominant action of these drugs in ulcerative colitis and Crohn's disease we cannot hope to design specific treatments aimed at altering particular aspects of the inflammatory response. The lack of animal models is a hindrance and at present studies have to be made on human tissue. Showing that corticosteroids inhibit prostaglandin synthesis in tissue culture of rectal biopsies from patients with ulcerative colitis is an example of a method which could be explored further. 4 Until more data of this type are available, we must make the best use possible of other measurements available to us. Therapeutic trials measure clinical response and by this means we can answer questions about the relative efficacy of different types of corticosteroid, of different dose schedules or modes of administration. or of the same treatment in different types of disease. The other measurement which can give useful information is that of drug levels in body fluids or tissues.
Techniques for the measurement of cortisol have yielded useful information about endogenous steroid secretion and treatment with corticotrophin or hydrocortisone itself. Even though drug levels can be measured the results are difficult to interpret in clinical terms because the biological effects of the drug on endogenous cortisol secretion, or on experimentally induced inflammation persist longer than would be predicted from the plasma level. Thus the plasma half-life of prednisolone after intravenous administration is around three to four hours, but the biological half-life is 18-36 hours.3 8 9 Furthermore, although anti-inflammatory activity appears to be quantitatively related to the concentration of active steroid in the tissue,3 no clear relation has been observed between plasma level achieved and the therapeutic response in colitis." 7 The situation is further complicated by the fact that therapeutic activity (and the liability to side effects) are related, not to total drug levels, but to drug levels unbound to protein. The main proteins concerned are transcortin (corticosteroid binding globulin) with low capacity and high affinity, and albumin, with high capacity but low affinity. It can be predicted that at low drug doses a greater proportion of the drug will be bound to protein than at higher doses and measurements show that with decreasing levels of serum albumin the proportion of free prednisolone rises with an associated increase in drug side effects."'
The elegant paper by Shaffer and his colleagues in this issue shows the value of studying corticosteroid absorption when the intestine is diseased. ". When compared with a normal control group, absorption of prednisolone given by mouth was reduced in seven patients with Crohn's disease as judged by isotopic measurements in plasma, urine, and faeces (three patients). All but one of the patients had ileal disease of mild to moderate severity, but there was no steatorrhoea or excess protein loss from the gut. These observations differ from those of Tanner et al who found, by measurement of prednisolone serum levels using a specific radioimmunoassay, that the mean peak levels and areas under the curve were not significantly different from normal in nine patients with Crohn's disease given 20 mg of prednisolone by mouth.'2 There was, however, greater variation in the patients than in the control subjects. Five of their nine patients had disease predominantly involving the colon and it is noteworthy that the two highest prednisolone levels recorded were in such patients, and the two lowest were in patients with small bowel involvement. Four of the five patients with colonic disease underwent colectomy and the authors comment that serum levels were particularly high in those with the most active disease. Levels of corticosteroid in body fluids are relatively easier to measure than the critical therapeutic levels in the inflamed tissue. Topical corticosteroids applied from the lumen of the gut, are frequently used in the treatment of inflammatory bowel disease with the aim of attaining high tissue levels in the involved mucosa and there is at present interest in the properties of corticosteroids which are poorly absorbed into the blood.25 2( Studies in the rat have shown that a well absorbed drug such as prednisolone enhances the absorptive and digestive capacities of enterocytes but has little effect on mucosal structure or cell kinetics. An equivalent dose of betamethasone-17-valerate, a locally acting corticosteroid, has a similar effect on the enterocytes, but also inhibits crypt cell turnover with marked hypoplasia of the jejunal mucosa.27 Careful studies of the effect of poorly absorbed corticosteroids on the mucosa of the normal small and large intestine are thus needed, in addition to therapeutic trials.
An outside observer could justly express some disappointment about the progress made over the last 27 years in exploiting the knowledge that cortisone can benefit a patient with colitis. New techniques and sharpening of interest may enable us to build more rapidly on the foundation of knowledge now available, so that we can learn in the next few years how to achieve maximal benefit with minimal adverse effects from these useful drugs. 
